Related articles
-
Article
Valeant’s financial restatement begs compliance questions
Valeant Pharmaceuticals’ announced financial restatement raises questions about the drug company’s compliance program and its business model. But it might also serve as an early warning to all publicly listed U.S. companies about the increased room for misjudging the booking of sales once FASB rolls out its new revenue recognition ...
-
News BriefFTC orders AI firms to disclose safeguards for children and teens
AI chatbots are increasingly used by children and teens, prompting the FTC to order seven AI companies to explain how they monitor potential harms to minors.
-
ArticleGoogle hit with $425.6 million verdict in California privacy case
Google allegedly collected personal data from mobile devices without permission, violating California privacy laws, a jury ruled in awarding more than $425.6 million to class-action plaintiffs.